Praxis Precision Medicines Inc Epilepsy Day Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Myles Minter from William Blair. Just on 222, have you disclosed your sort of target dose that you're looking to see with the intrathecal administration there to achieve that 35% knockdown. I'm curious whether it's up towards the 80 milligrams or above, which are -- might raise those tominersen issues that we've seen in HTT lowering.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : And then maybe on 114, we saw that in the slides. Why haven't we seen a trial started in epilepsy comorbid with depression? Are you waiting for Aria to read out on that one?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Yes, Myles from Blair again. You presented some pretty interesting data on the number of like medications that are used in these patients. It seems to be a lot, and I'm particularly interested, if you do get PRAX-222 to lower -- to 35% knockdown and you're on background like sodium channel blockers, how are you going to control for that use, like if that pushes you further down the functional knockdown, so the threshold? And especially if you start controlling for that use, what happens to the other 8 antiseizure medications that these patients are on. And I mean is that a problem that you see in the clinic, Dr. Friedman? And are you concerned about that? I'd like to hear comments from both the company and you. Daniel Friedman I mean from a practical standpoint, we use medications with overlapping mechanisms all the time. And sometimes it works and we don't -- and they work in combination, but not alone, so -- to sodium channel blockers. So I think that -- I don't think that sort of 2 therapies targeting the same mechanism would present a problem for me in terms of interpreting the data as long as the groups are balanced in terms of overall agents used.